|
AIM IMMUNOTECH Inc. (AIM) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
AIM ImmunoTech Inc. (AIM) Bundle
Conçu pour la précision, notre calculatrice AIM DCF vous permet d'évaluer l'évaluation AIM Immunotech Inc. (AIM) à l'aide de données financières du monde réel, offrant une flexibilité complète pour modifier tous les paramètres essentiels pour des projections améliorées.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .2 | .1 | .1 | .2 | .2 | .2 | .2 | .2 | .2 | .2 |
| Revenue Growth, % | 0 | -17.18 | 4.44 | 43.26 | -15.84 | 3.67 | 3.67 | 3.67 | 3.67 | 3.67 |
| EBITDA | -13.0 | -18.3 | -19.9 | -31.7 | .0 | -.1 | -.1 | -.2 | -.2 | -.2 |
| EBITDA, % | -7988.96 | -13522.22 | -14091.49 | -15682.18 | 0 | -80 | -80 | -80 | -80 | -80 |
| Depreciation | .7 | .8 | -.4 | .2 | .0 | .1 | .1 | .1 | .1 | .1 |
| Depreciation, % | 433.13 | 596.3 | -300.71 | 117.82 | 0 | 40 | 40 | 40 | 40 | 40 |
| EBIT | -13.7 | -19.1 | -19.4 | -31.9 | .0 | -.1 | -.1 | -.2 | -.2 | -.2 |
| EBIT, % | -8422.09 | -14118.52 | -13790.78 | -15800 | 0 | -80 | -80 | -80 | -80 | -80 |
| Total Cash | 39.0 | 48.3 | 34.2 | 13.1 | 2.3 | .2 | .2 | .2 | .2 | .2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.1 | 1.6 | 1.7 | 1.2 | .0 | .1 | .1 | .2 | .2 | .2 |
| Account Receivables, % | 689.57 | 1215.56 | 1188.65 | 586.14 | 0 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | .0 | -.3 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | -149.5 | 0 | -20 | -20 | -20 | -20 | -20 |
| Accounts Payable | .4 | .2 | .4 | 6.4 | .0 | .1 | .1 | .2 | .2 | .2 |
| Accounts Payable, % | 234.97 | 146.67 | 267.38 | 3189.6 | 0 | 80 | 80 | 80 | 80 | 80 |
| Capital Expenditure | -.6 | -.6 | -.3 | -.6 | .0 | -.1 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -365.03 | -468.89 | -192.2 | -289.6 | -10.59 | -82.12 | -82.12 | -82.12 | -82.12 | -82.12 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -15.5 | -21.4 | -21.1 | -31.9 | .0 | -.1 | -.1 | -.2 | -.2 | -.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.1 | -22.0 | -21.6 | -25.4 | -5.6 | -.2 | -.2 | -.2 | -.2 | -.2 |
| WACC, % | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -6 | |||||||||
| Present Terminal Value | -5 | |||||||||
| Enterprise Value | -6 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -6 | |||||||||
| Diluted Shares Outstanding, MM | 56 | |||||||||
| Equity Value Per Share | -0.10 |
What You Will Get
- Pre-Filled Financial Model: AIM ImmunoTech Inc.'s (AIM) actual data provides an accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Instant Calculations: Automatic updates allow you to view results in real-time as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for comprehensive forecasts.
Key Features
- Customizable Research Parameters: Adjust key metrics such as clinical trial phases, market potential, and regulatory timelines.
- Instant Valuation Calculations: Automatically computes intrinsic value, NPV, and other financial metrics with ease.
- High-Precision Analysis: Leverages AIM ImmunoTech's actual financial data for credible valuation insights.
- Effortless Scenario Testing: Explore various hypotheses and evaluate their impacts effortlessly.
- Efficiency Booster: Streamline the valuation process without the hassle of creating complex models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered AIM ImmunoTech Inc. (AIM) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for AIM ImmunoTech Inc.'s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose AIM ImmunoTech Inc. (AIM)?
- Innovative Solutions: Pioneering research and development in immunotherapy.
- Proven Results: Backed by scientific studies demonstrating efficacy and safety.
- Strong Pipeline: A diverse range of promising therapies in various stages of development.
- Expert Team: Led by seasoned professionals with extensive industry experience.
- Commitment to Patients: Focused on improving patient outcomes and quality of life.
Who Should Use This Product?
- Investors: Assess AIM ImmunoTech Inc.'s (AIM) potential value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for accurate financial reporting and analysis related to AIM.
- Consultants: Efficiently modify the template for valuation reports tailored to AIM's clients.
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech companies like AIM.
- Educators: Incorporate it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Historical Data: Includes AIM ImmunoTech Inc.'s (AIM) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate AIM ImmunoTech Inc.'s (AIM) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of AIM ImmunoTech Inc.'s (AIM) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.